Antineurofilament and antiretinal antibodies in AIDS patients with cytomegalovirus retinitis.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Antineurofilament and antiretinal antibodies in AIDS patients with cytomegalovirus retinitis.

Clin Diagn Lab Immunol. 1994 Jul;1(4):445-9. Unique Identifier : AIDSLINE MED/96050853
Rosberger DF; Tshering SL; Polsky B; Heinemann MH; Klein RF; Cunningham-Rundles S; Department of Ophthalmology, Cornell University Medical College,; New York, New York 10021, USA.

Abstract: Sera obtained from AIDS patients with cytomegalovirus (CMV) retinitis before and after treatment with foscarnet, AIDS patients with human immunodeficiency virus (HIV) retinopathy, AIDS patients without retinal disease, and normal healthy controls with and without positive CMV serologies were assayed for the presence of antibodies against the 200-kDa outer, 160-kDa middle, and 68-kDa core subunits of the neurofilament triplet. Additional studies were performed to determine the presence of antibodies reactive with proteins extracted from crude human retinal antigen preparations. Antibodies against the 200-, 260-, and 68-kDa proteins of the neurofilament triplet were detected in 15 of 15 AIDS patients with CMV retinitis. The expression of these antibodies was unaffected, qualitatively, by successful treatment with foscarnet. In contrast, only 30% of patients with HIV retinopathy unrelated to CMV, fewer than 35% of AIDS patients with positive CMV titers but without evident retinitis, and fewer than 25% of healthy controls with positive or negative CMV titers possessed antibodies against any of the triplet proteins (P < 0.001). Antibodies against several clusters of retinal antigens were also identified in the sera of patients with CMV retinitis. In summary, the data indicate that retinal elements damaged by CMV infection induce an antibody response against the 200-, 160-, and 68kDa components of the neurofilament triplet as well as other, as yet undefined retinal antigens.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/*IMMUNOLOGY Antibodies/*BLOOD Antiviral Agents/ADMINISTRATION & DOSAGE Comparative Study Cytomegalovirus Retinitis/DIAGNOSIS/*IMMUNOLOGY Foscarnet/ADMINISTRATION & DOSAGE Human Male Necrosis Neurofilament Proteins/*IMMUNOLOGY Retina/*IMMUNOLOGY/PATHOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
960530
M9651020

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .